Immunovant (IMVT)

• Market cap: $4.04B
• 1 day: 0.25%
• 5 days: 4.79%
• 1 month: -14.51%
• 3 months: -18.46%
• 6 months: -20.41%
• Year to date: -5.28%
• 1 year: -41.75%
• 5 years: 40.35%
• 10 years: 139.80%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).

Employees: 207

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

226% more call options, than puts

Call options by funds: $71.2M | Put options by funds: $21.8M

40% more funds holding in top 10

Funds holding in top 10: 5 [Q2] → 7 (+2) [Q3]

12% more capital invested

Capital invested by funds: $2.02B [Q2] → $2.26B (+$240M) [Q3]

1.79% more ownership

Funds ownership: 52.27% [Q2] → 54.06% (+1.79%) [Q3]

9% more repeat investments, than reductions

Existing positions increased: 71 | Existing positions reduced: 65

8% less funds holding

Funds holding: 197 [Q2] → 181 (-16) [Q3]

42% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 36

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $45 89% upside
• Avg. target: $47 97% upside
• High target: $51 114% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

B of A Securities Jason Gerberry 60% 1-year accuracy 12 / 20 met price target	89% upside $45	Buy Maintained	15 Jan 2025
Wells Fargo Derek Archila 44% 1-year accuracy 16 / 36 met price target	89% upside $45	Overweight Maintained	19 Dec 2024
HC Wainwright & Co. Douglas Tsao 33% 1-year accuracy 56 / 172 met price target	114% upside $51	Buy Reiterated	8 Nov 2024